Gross Profit Analysis: Comparing Jazz Pharmaceuticals plc and Vericel Corporation

Jazz vs. Vericel: A Decade of Gross Profit Growth

__timestampJazz Pharmaceuticals plcVericel Corporation
Wednesday, January 1, 2014105545700011503000
Thursday, January 1, 2015122227700024698000
Friday, January 1, 2016138258700026076000
Sunday, January 1, 2017150850500033570000
Monday, January 1, 2018176937800058697000
Tuesday, January 1, 2019203383100080279000
Wednesday, January 1, 2020221465000084228000
Friday, January 1, 20212653478000106025000
Saturday, January 1, 20223118857000109788000
Sunday, January 1, 20233398627000135576000
Loading chart...

Cracking the code

Gross Profit Growth: Jazz Pharmaceuticals vs. Vericel Corporation

In the competitive landscape of the pharmaceutical industry, understanding financial performance is crucial. Jazz Pharmaceuticals and Vericel Corporation, two prominent players, have shown distinct trajectories in their gross profit over the past decade. From 2014 to 2023, Jazz Pharmaceuticals has experienced a robust growth, with its gross profit increasing by over 220%, reaching approximately $3.4 billion in 2023. This growth reflects Jazz's strategic expansions and successful product lines.

In contrast, Vericel Corporation, while smaller in scale, has demonstrated a commendable growth of over 1,000% in the same period, albeit from a lower base, reaching around $135 million in 2023. This indicates Vericel's potential in niche markets and innovative therapies. The data highlights the dynamic nature of the pharmaceutical sector, where both large and small companies can thrive through strategic focus and innovation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025